JO
SYRE icon

John Overdeck’s Spyre Therapeutics SYRE Stock Holding History

John Overdeck’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.13M Buy
+12,771
New +$932K ﹤0.01% 3516
2025
Q1 		– Sell
-9,638
Closed -$224K – 3477
2024
Q4 		$224K Sell
9,638
-165
-2% -$4.84K ﹤0.01% 2841
2024
Q3 		$288K Sell
9,803
-39
-0.4% -$1.09K ﹤0.01% 2684
2024
Q2 		$231K Sell
9,842
-3,513
-26% -$118K ﹤0.01% 2690
2024
Q1 		$507K Sell
13,355
-14,740
-52% -$427K ﹤0.01% 2329
2023
Q4 		$605K Buy
+28,095
New +$387K ﹤0.01% 2359
2023
Q2 		– Sell
-12,820
Closed -$92.9K – 3253
2023
Q1 		$92.9K Sell
12,820
-2,926
-19% -$32.1K ﹤0.01% 2681
2022
Q4 		$177K Buy
15,746
+11,602
+280% +$209K ﹤0.01% 2419
2022
Q3 		$54K Sell
4,144
-8,490
-67% -$105K ﹤0.01% 2309
2022
Q2 		$160K Buy
12,634
+3,970
+46% +$139K ﹤0.01% 2205
2022
Q1 		$498K Buy
8,664
+6,084
+236% +$511K ﹤0.01% 2013
2021
Q4 		$306K Buy
+2,580
New +$407K ﹤0.01% 3640
2021
Q2 		– Sell
-733
Closed -$145K – 4543
2021
Q1 		$145K Sell
733
-1,838
-71% -$353K ﹤0.01% 3676
2020
Q4 		$506K Sell
2,571
-3,060
-54% -$634K ﹤0.01% 2510
2020
Q3 		$998K Buy
5,631
+2,334
+71% +$432K ﹤0.01% 1759
2020
Q2 		$762K Buy
3,297
+1,880
+133% +$358K ﹤0.01% 1712
2020
Q1 		$165K Sell
1,417
-568
-29% -$96.6K ﹤0.01% 2717
2019
Q4 		$379K Buy
+1,985
New +$390K ﹤0.01% 3011
2019
Q3 		– Sell
-1,978
Closed -$339K – 3779
2019
Q2 		$339K Buy
+1,978
New +$342K ﹤0.01% 2786
2018
Q4 		– Sell
-1,055
Closed -$252K – 3504
2018
Q3 		$252K Buy
1,055
+574
+119% +$134K ﹤0.01% 2876
2018
Q2 		$127K Buy
+481
New +$118K ﹤0.01% 3188

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

John Overdeck's SYRE Position: Q2 2026 in Review

John Overdeck opened a new position in Spyre Therapeutics (SYRE) in Q2 2026: 12,771 shares worth $1.13M. The stake represents ﹤0.01% of the portfolio and ranks #3516 among its holdings. This is a return to the name: John Overdeck previously reported a position in SYRE as recently as Q4 2024.

John Overdeck first reported a position in SYRE in Q2 2018 and has held it in 21 quarters since. 263 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • John Overdeck held 12,771 shares of Spyre Therapeutics worth $1.13M as of Q2 2026.
  • Spyre Therapeutics was a new John Overdeck position in Q2 2026.
  • Spyre Therapeutics made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #3516 holding.
  • John Overdeck first reported a position in Spyre Therapeutics in Q2 2018 and has held it in 21 quarters since.
  • 263 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.